
    
      The aim of this study is to include 40 patients with middle-advanced Hepatocellular Carcinoma
      .These patients were randomly allocated to TACE treatment group or TACE+Anlotinib treatment
      group.The treatment effectiveness, local tumor control and survival outcome between the two
      groups were compared.
    
  